# US 2003/0204069 A1 · Segments of the human gene for telomerase reverse transcriptase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0204069 A1
- Document ID: US20030204069A1
- Status: Published application
- Kind: A1
- Application number: 10/325,810
- Filed: 2002-12-20
- Published: 2003-10-30
- Earliest claimed: 1997-08-14
- Assignees: Geron Corporation
- Inventors: Gregg B. Morin; William H. Andrews
- Web page: https://patentgrep.com/patent/US20030204069A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/40: against enzymes
- C12N 9/1241: {Nucleotidyltransferases (2.7.7)}
- C12N 9/1276: {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Y 207/07049: RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
- G01N 33/575: for cancer
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2319/00: Fusion polypeptide
- C12N 2310/15: Nucleic acids forming more than 2 strands, e.g. TFOs
- C12N 2310/315: Phosphorothioates
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- G01N 2333/9125: with a definite EC number (2.7.7.-)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

## Claims

### Claim 1

An isolated polynucleotide from the gene for human telomerase reverse transcriptase (hTRT) comprising a sequence having at least one of the following features:
a) it contains at least 25 consecutive nucleotides within SEQ. ID NO:6 but not within SEQ. ID NO:1.
b) it is complementary to a); or
c) it contains at least 25 consecutive nucleotides within the insert of Lambda phage GΦ5 (ATCC Accession No. 98505), but not within the insert of Lambda phage 25-1.1 (ATCC Accession No. 209024).

### Claim 2 (depends on 1)

The polynucleotide of claim 1, wherein said sequence contains at least 25 consecutive nucleotides within SEQ. ID NO:6 but not within SEQ. ID NO: 1, or the complement thereof.

### Claim 3 (depends on 1)

The polynucleotide of claim 1, wherein said sequence contains at least 50 consecutive nucleotides within SEQ. ID NO:6 but not within SEQ. ID NO: 1, or the complement thereof.

### Claim 4 (depends on 1)

The polynucleotide of claim 1, wherein said sequence contains at least 100 consecutive nucleotides within SEQ. ID NO:6 but not within SEQ. ID NO:1, or the complement thereof.

### Claim 5 (depends on 1)

The polynucleotide of claim 1, wherein said sequence contains at least 200 consecutive nucleotides within SEQ. ID NO:6 but not within SEQ. ID NO: 1, or the complement thereof.

### Claim 6 (depends on 1)

The polynucleotide of claim 1, wherein said sequence contains at least 500 consecutive nucleotides within SEQ. ID NO:6 but not within SEQ. ID NO: 1, or the complement thereof.

### Claim 7 (depends on 1)

The polynucleotide of claim 1, wherein said sequence contains at least 25 consecutive nucleotides within the BglII-FSPI fragment in the insert of Lambda phage GΦ5, but not within the insert of Lambda phage 25-1.1.

### Claim 8 (depends on 7)

The polynucleotide of claim 7, wherein said sequence contains at least 50 consecutive nucleotides within said fragment.

### Claim 9 (depends on 7)

The polynucleotide of claim 7, wherein said sequence contains at least 100 consecutive nucleotides within said fragment.

### Claim 10 (depends on 1)

The polynucleotide of claim 1, wherein said sequence contains at least 200 consecutive nucleotides within said fragment.

### Claim 11 (depends on 1)

The polynucleotide of claim 1, wherein said sequence contains at least 500 consecutive nucleotides within said fragment.

### Claim 12 (depends on 1)

The polynucleotide of claim 1, wherein said sequence is within 1.8 kilobases upstream of the translation initiation site.

### Claim 13 (depends on 3)

The polynucleotide of claim 3, wherein said sequence is within 1.8 kilobases upstream of the translation initiation site.

### Claim 14 (depends on 8)

The polynucleotide of claim 8, wherein said sequence is within 1.8 kilobases upstream of the translation initiation site.

### Claim 15 (depends on 1)

The polynucleotide of claim 1, which promotes transcription in cells endogenously expressing hTRT.

### Claim 16 (depends on 1)

A method of gene expression, comprising expressing a heterologous gene in a cell under control of the polynucleotide of claim 1.

### Claim 17 (depends on 16)

The method of claim 16, wherein the heterologous gene is a reporter gene.

### Claim 18 (depends on 17)

The method of claim 17, wherein the reporter gene is luciferase, glucuronidase, galactosidase, chloramphenicol acetyl transferase, green fluorescent protein (GFP) or alkaline phosphatase.

### Claim 19 (depends on 16)

The method of claim 16, conducted in order to measure a cis or trans transcriptional regulatory factor that regulates transcription of hTRT.

### Claim 20 (depends on 16)

The method of claim 16, conducted for the purpose of drug screening.
